Evidence map›Paper›PMID 40413269›Full record

ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2025

Bilirubin metabolism and its application in disease prevention: mechanisms and research advances.

Yue Zhang, Haoni Luan, Peng Song

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Mild isolated hyperbilirubinemia in donors and short-term post-liver transplant survival in their recipients: A propensity-matched analysis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Observational
  10. Observational
  11. Review
  12. Article
  13. Article
  14. Disrupted terminal bilirubin catabolism linksFrontiers in microbiology · 2026
    Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yue ZhangSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China.
Haoni LuanSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China.
Peng SongSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China. songpeng@lcu.edu.cn.

Funding

Natural Science Foundation of Shandong Province ZR2022MC159
6 · The paper itself

Abstract

The role of bilirubin, a product of heme metabolism, has evolved from a traditionally perceived metabolic waste product to a critical molecule with diverse biological roles. This article comprehensively reviews the metabolic functions of bilirubin and advances in its application for disease prevention. Bilirubin is primarily derived from hemoglobin catabolism in senescent erythrocytes. It is subsequently metabolized and excreted by the liver through tightly regulated processes involving enzymes, nuclear receptors, hormones, and pharmaceuticals. Bilirubin exhibits diverse physiological functions, including antioxidant, anti-inflammatory, and immunomodulatory activities. Owing to its unique chemical structure, bilirubin scavenges free radicals, inhibits lipid peroxidation, and protects cells across multiple systems. By suppressing the NF-κB signaling pathway, it reduces inflammatory factor release and mitigates chronic inflammation. Additionally, it modulates immune cell activity to maintain homeostasis, offering therapeutic potential for autoimmune and infectious diseases. Bilirubin demonstrates significant potential in disease prevention. In cardiovascular diseases, it attenuates atherosclerosis and mitigates myocardial ischemia/reperfusion injury. For metabolic disorders, it improves insulin resistance, regulates blood glucose, and reduces hepatic steatosis, offering therapeutic benefits for diabetes and non-alcoholic fatty liver disease. In neurological conditions, its antioxidant and anti-inflammatory properties hold promise for preventing and managing neurodegenerative diseases and neonatal bilirubin encephalopathy. Although research on bilirubin has advanced significantly, its intracellular targets and molecular interaction networks remain incompletely understood, and numerous challenges hinder its clinical translation. Future efforts should leverage multi-omics technologies to elucidate its mechanisms, develop intelligent and personalized therapeutics, and conduct large-scale clinical trials to accelerate translational applications and improve patient outcomes.

Indexed as

BilirubinAnimalsAnti-Inflammatory AgentsAntioxidantsCardiovascular DiseasesHumansMetabolic DiseasesAnti-Inflammatory AgentsAntioxidantsBilirubinAnti-inflammatoryAntioxidantBilirubinImmunomodulationNanoparticles

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.